{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:47:33Z","timestamp":1789778853424,"version":"4.0.1"},"reference-count":66,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Heart failure is a common debilitating illness, associated with significant morbidity and mortality, rehospitalisation and societal costs. Current guidelines and position statements emphasise the management of patients with overt symptomatic disease, but the increasing prevalence of congestive heart failure underscores the need to identify and manage patients with early left ventricular dysfunction prior to symptom onset. Asymptomatic left ventricular systolic dysfunction (ALVSD), classified as stage B heart failure, is defined as depressed left ventricular systolic function in the absence of clinical heart failure. Early initiation of therapies in patients with presumed ALVSD has been shown to lead to better outcomes. In this article, the authors clarify issues surrounding the definition and natural history of ALVSD, outline clinical tools that may be of value in identifying patients with ALVSD and highlight potential opportunities for future investigations to better address aspects of our understanding of this complex syndrome.<\/jats:p>","DOI":"10.15420\/ecr.2019.14","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T10:35:13Z","timestamp":1585132513000},"source":"Crossref","is-referenced-by-count":36,"title":["Asymptomatic Left Ventricle Systolic Dysfunction"],"prefix":"10.15420","volume":"15","author":[{"given":"Jaskanwal D","family":"Sara","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Toya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, US; Division of Cardiology, National Defense Medical College, Tokorozawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, US;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Lerman","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, US;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gersh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, US;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandan S","family":"Anavekar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, US;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"ref0","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics \u2013 2015 update: a report from the American Heart Association. Circulation 2015;131:e29\u2013322. https:\/\/doi.org\/10.1161\/CIR.0000000000000152; PMID: 26078378."},{"key":"ref1","unstructured":"DeFrances CJ, Podgornik MN. 2004 National hospital discharge survey. Adv Data 2006;(371):1\u201319. PMID: 16703980."},{"key":"ref2","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128; PMID: 27206819."},{"key":"ref3","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failur. Circulation 2017;136:e137\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025; PMID: 28461007."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685\u201391. https:\/\/doi.org\/10.1056\/NEJM199209033271003; PMID: 1463530.","DOI":"10.1056\/nejm199209033271003"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial-infarction \u2013 results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992;327:669\u201377. https:\/\/doi.org\/10.1056\/NEJM199209033271001; PMID: 1386652.","DOI":"10.1056\/nejm199209033271001"},{"key":"ref6","unstructured":"Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263\u201376. https:\/\/doi.org\/10.1016\/1047-2797(91)90005-W; PMID: 1669507."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Pandhi J, Gottdiener JS, Bartz TM, et al. Comparison of characteristics and outcomes of asymptomatic versus symptomatic left ventricular dysfunction in subjects 65 years old or older (from the Cardiovascular Health Study). Am J Cardiol 2011;107:1667\u201374. https:\/\/doi.org\/10.1016\/j.amjcard.2011.01.051; PMID: 21575752.","DOI":"10.1016\/j.amjcard.2011.01.051"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community. Circulation 2007;115:1563\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.666818; PMID: 17353436.","DOI":"10.1161\/circulationaha.106.666818"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977\u201382. https:\/\/doi.org\/10.1161\/01.CIR.0000085166.44904.79; PMID: 12912813.","DOI":"10.1161\/01.cir.0000085166.44904.79"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis. JACC Heart Fail 2016;4:237\u201348. https:\/\/doi.org\/10.1016\/j.jchf.2015.09.015; PMID: 26682794.","DOI":"10.1016\/j.jchf.2015.09.015"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Galasko GI, Barnes SC, Collinson P, et al. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J 2006;27:193\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehi559; PMID: 16267076.","DOI":"10.1093\/eurheartj\/ehi559"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(97)03033-X; PMID: 9310600.","DOI":"10.1016\/s0140-6736(97)03033-x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631\u20139. https:\/\/doi.org\/10.7326\/0003-4819-137-8-200210150-00006; PMID: 12379062.","DOI":"10.7326\/0003-4819-137-8-200210150-00006"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736\u201342. https:\/\/doi.org\/10.1016\/S0735-1097(03)00789-7; PMID: 12932612.","DOI":"10.1016\/s0735-1097(03)00789-7"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Aljaroudi W, Alraies MC, Halley C, et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012;125:782\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.066423; PMID: 22261198.","DOI":"10.1161\/circulationaha.111.066423"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Moller JE, Sondergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study. J Am Coll Cardiol 2000;36:1841\u20136. https:\/\/doi.org\/10.1016\/S0735-1097(00)00965-7; PMID: 11092654.","DOI":"10.1016\/s0735-1097(00)00965-7"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Cikes M, Solomon SD. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J 2016;37:1642\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehv510; PMID: 26417058.","DOI":"10.1093\/eurheartj\/ehv510"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Potter E, Marwick TH. Assessment of left ventricular function by echocardiography: the case for routinely adding global longitudinal strain to ejection fraction. JACC Cardiovasc Imaging 2018;11:260\u201374. https:\/\/doi.org\/10.1016\/j.jcmg.2017.11.017; PMID: 29413646.","DOI":"10.1016\/j.jcmg.2017.11.017"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Zhang KW, French B, May Khan A, et al. Strain improves risk prediction beyond ejection fraction in chronic systolic heart failure. J Am Heart Assoc 2014;3:e000550. https:\/\/doi.org\/10.1161\/JAHA.113.000550; PMID: 24419736.","DOI":"10.1161\/jaha.113.000550"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Sengelov M, Jorgensen PG, Jensen JS, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. JACC Cardiovasc Imaging 2015;8:1351\u20139. https:\/\/doi.org\/10.1016\/j.jcmg.2015.07.013; PMID: 26577264.","DOI":"10.1016\/j.jcmg.2015.07.013"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hung CL, Verma A, Uno H, et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 2010;56:1812\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2010.06.044; PMID: 21087709.","DOI":"10.1016\/j.jacc.2010.06.044"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009;2:356\u201364. https:\/\/doi.org\/10.1161\/CIRCIMAGING.109.862334; PMID: 19808623.","DOI":"10.1161\/circimaging.109.862334"},{"key":"ref23","unstructured":"Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911\u201339. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012; PMID: 25172399."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63:2751\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.073; PMID: 24703918.","DOI":"10.1016\/j.jacc.2014.01.073"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Szelenyi Z, Fazakas A, Szenasi G, et al. The mechanism of reduced longitudinal left ventricular systolic function in hypertensive patients with normal ejection fraction. 2015;33:1962\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000000624; PMID: 26154942.","DOI":"10.1097\/hjh.0000000000000624"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Lee WH, Liu YW, Yang LT, Tsai WC. Prognostic value of longitudinal strain of subepicardial myocardium in patients with hypertension. J Hypertens 2016;34:1195\u2013200. https:\/\/doi.org\/10.1097\/HJH.0000000000000903; PMID: 27035737.","DOI":"10.1097\/hjh.0000000000000903"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Holland DJ, Marwick TH, Haluska BA, et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart 2015;101:1061\u20136. https:\/\/doi.org\/10.1136\/heartjnl-2014-307391; PMID: 25935767.","DOI":"10.1136\/heartjnl-2014-307391"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kiencke S, Handschin R, von Dahlen R, et al. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail 2010;12:951\u20137. https:\/\/doi.org\/10.1093\/eurjhf\/hfq110; PMID: 20581103.","DOI":"10.1093\/eurjhf\/hfq110"},{"key":"ref29","unstructured":"Liu JH, Chen Y, Yuen M, et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2016;15:22. https:\/\/doi.org\/10.1186\/s12933-016-0333-5; PMID: 26842466."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Yingchoncharoen T, Gibby C, Rodriguez LL, et al. Association of myocardial deformation with outcome in asymptomatic aortic stenosis with normal ejection fraction. Circ Cardiovasc Imaging 2012;5:719\u201325. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.977348; PMID: 23008423.","DOI":"10.1161\/circimaging.112.977348"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Citro R, Baldi C, Lancellotti P, et al. Global longitudinal strain predicts outcome after MitraClip implantation for secondary mitral regurgitation. J Cardiovasc Med (Hagerstown) 2017;18:669\u201378. https:\/\/doi.org\/10.2459\/JCM.0000000000000526; PMID: 28509760.","DOI":"10.2459\/jcm.0000000000000526"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Ewe SH, Haeck MLA, Ng ACT, et al. Detection of subtle left ventricular systolic dysfunction in patients with significant aortic regurgitation and preserved left ventricular ejection fraction: speckle tracking echocardiographic analysis. Eur Heart J Cardiovasc Imaging 2015;16:992\u20139. https:\/\/doi.org\/10.1093\/ehjci\/jev019; PMID: 25733208.","DOI":"10.1093\/ehjci\/jev019"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90:29\u201334. https:\/\/doi.org\/10.1016\/S0002-9149(02)02381-0; PMID: 12088775.","DOI":"10.1016\/s0002-9149(02)02381-0"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218\u201323. https:\/\/doi.org\/10.1016\/j.ahj.2003.10.005; PMID: 14760316.","DOI":"10.1016\/j.ahj.2003.10.005"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Obokata M, Nagata Y, Wu VC, et al. Direct comparison of cardiac magnetic resonance feature tracking and 2D\/3D echocardiography speckle tracking for evaluation of global left ventricular strain. Eur Heart J Cardiovasc Imaging 2016;17:525\u201332. https:\/\/doi.org\/10.1093\/ehjci\/jev227; PMID: 26377901.","DOI":"10.1093\/ehjci\/jev227"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724\u20139. https:\/\/doi.org\/10.1161\/01.CIR.82.5.1724; PMID: 2146040","DOI":"10.1161\/01.cir.82.5.1724"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996;94:690\u20137. https:\/\/doi.org\/10.1161\/01.CIR.94.4.690; PMID: 8772689.","DOI":"10.1161\/01.cir.94.4.690"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799\u2013807. https:\/\/doi.org\/10.1053\/euhj.1999.1746; PMID: 10581138.","DOI":"10.1053\/euhj.1999.1746"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002;359:1430\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(02)08358-7; PMID: 11978359.","DOI":"10.1016\/s0140-6736(02)08358-7"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Kelly R, Struthers AD. Screening for left ventricular systolic dysfunction in patients with stroke, transient ischaemic attacks, and peripheral vascular disease. QJM 1999;92:295\u20137. https:\/\/doi.org\/10.1093\/qjmed\/92.6.295; PMID: 10616704.","DOI":"10.1093\/qjmed\/92.6.295"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 2002;288:1252\u20139. https:\/\/doi.org\/10.1001\/jama.288.10.1252; PMID: 12215132.","DOI":"10.1001\/jama.288.10.1252"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588; PMID: 23821090.","DOI":"10.1001\/jama.2013.7588"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013;62:1365\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.069; PMID: 23810874.","DOI":"10.1016\/j.jacc.2013.05.069"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med 2019;25:70\u201374. https:\/\/doi.org\/10.1038\/s41591-018-0240-2; PMID: 30617318.","DOI":"10.1038\/s41591-018-0240-2"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168\u201375. https:\/\/doi.org\/10.1161\/01.ATV.0000051384.43104.FC; PMID: 12588755.","DOI":"10.1161\/01.atv.0000051384.43104.fc"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Fujisue K, Sugiyama S, Matsuzawa Y, et al. Prognostic significance of peripheral microvascular endothelial dysfunction in heart failure with reduced left ventricular ejection fraction. Circ J 2015;79:2623\u201331. https:\/\/doi.org\/10.1253\/circj.CJ-15-0671; PMID: 26489455.","DOI":"10.1253\/circj.cj-15-0671"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Yufu K, Shinohara T, Ebata Y, et al. Endothelial function predicts new hospitalization due to heart failure following cardiac resynchronization therapy. Pacing Clin Electrophysiol 2015;38:1260\u20136. https:\/\/doi.org\/10.1111\/pace.12698; PMID: 26227741.","DOI":"10.1111\/pace.12698"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589\u201396. https:\/\/doi.org\/10.1161\/01.CIR.84.4.1589; PMID: 1914099.","DOI":"10.1161\/01.cir.84.4.1589"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996;28:585\u201390. https:\/\/doi.org\/10.1016\/0735-1097(96)00204-5; PMID: 8772743.","DOI":"10.1016\/0735-1097(96)00204-5"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine\u2013nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999;99:2113\u20137. https:\/\/doi.org\/10.1161\/01.CIR.99.16.2113; PMID: 10217650.","DOI":"10.1161\/01.cir.99.16.2113"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010;56:845\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.077; PMID: 20813282.","DOI":"10.1016\/j.jacc.2010.03.077"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50:2136\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2007.07.078; PMID: 18036451.","DOI":"10.1016\/j.jacc.2007.07.078"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001;98:5780\u20135. https:\/\/doi.org\/10.1073\/pnas.091415198; PMID: 11331753.","DOI":"10.1073\/pnas.091415198"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996;93:210\u20134. https:\/\/doi.org\/10.1161\/01.CIR.93.2.210; PMID: 8548890.","DOI":"10.1161\/01.cir.93.2.210"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Prasad A, Higano ST, Al Suwaidi J, et al. Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am Heart J 2003;146:549\u201354. https:\/\/doi.org\/10.1016\/S0002-8703(03)00364-8; PMID: 12947377.","DOI":"10.1016\/s0002-8703(03)00364-8"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Bank AJ, Lee PC, Kubo SH. Endothelial dysfunction in patients with heart failure: relationship to disease severity. J Card Fail 2000;6:29\u201336. https:\/\/doi.org\/10.1016\/S1071-9164(00)00009-9; PMID: 10746816.","DOI":"10.1016\/s1071-9164(00)00009-9"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Nohria A, Gerhard-Herman M, Creager MA, et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol (1985) 2006;101:545\u20138. https:\/\/doi.org\/10.1152\/japplphysiol.01285.2005; PMID: 16614356.","DOI":"10.1152\/japplphysiol.01285.2005"},{"key":"ref58","unstructured":"American College of Cardiology Foundation Appropriate Use Criteria Task Force; American Society of Echocardiography; American Heart Association, et al. ACCF\/ASE\/AHA\/ASNC\/HFSA\/HRS\/SCAI\/SCCM\/SCCT\/SCMR 2011 appropriate use criteria for echocardiography. J Coll Am Cardiol 2011;57:1126\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.002; PMID: 21349406."},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670\u20136. https:\/\/doi.org\/10.1056\/NEJM199512213332503; PMID: 7477219","DOI":"10.1056\/nejm199512213332503"},{"key":"ref60","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655; PMID: 31475794."},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)32484-X; PMID: 30429050.","DOI":"10.1016\/s0140-6736(18)32484-x"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720; PMID: 26378978.","DOI":"10.1056\/nejmoa1504720"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925; PMID: 28605608.","DOI":"10.1056\/nejmoa1611925"},{"key":"ref64","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389; PMID: 30415602."},{"key":"ref65","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303; PMID: 31535829."}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2019.14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T11:01:28Z","timestamp":1613818888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2019.14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":66,"URL":"https:\/\/doi.org\/10.15420\/ecr.2019.14","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"article-number":"e13"}}